Industry Spotlight: NKGen Biotech

About NKGen Biotech

NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell therapies

NK cell adoptive immunotherapy enhances a patient’s ability to destroy abnormal cells.

The mission of NKGen Biotech is to improve patients’​ lives in a safe and natural way through innovative cell therapy products and to ultimately become the global leader in immune cell therapeutics.

NKGen Biotech is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with cancer and neurodegenerative conditions.

SNK01, NKGen Biotech’s first cell therapy candidate, has planned clinical trials in several therapeutic areas, including oncology and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas.

More information can be found on NKGen Biotech website

Paul Song MD, NKGen Biotech CEO at BRAIN Synchrony Symposium